Drug Profile

Misetionamide - Geistlich/Panavance Therapeutics

Alternative Names: GP-2250; substance 2250; Taurultam analogue

Latest Information Update: 19 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Geistlich; Panavance Therapeutics
Developer Geistlich; Panavance Therapeutics; Ruhr-University Bochum
Class Alkanesulfonic acids; Antibacterials; Antineoplastics; Small molecules; Thiadiazines
Mechanism of Action Apoptosis stimulants; Glyceraldehyde 3 phosphate dehydrogenase inhibitors; Ketoglutarate dehydrogenase complex inhibitors; Lipopolysaccharide inhibitors; NF-kappa B kinase inhibitors; Proto-oncogene protein c-myc inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity Yes
Available For Licensing Yes

Phase I Pancreatic cancer
Preclinical Breast cancer; Cancer; Colorectal cancer; Malignant melanoma; Mesothelioma; Neuroendocrine tumours; Ovarian cancer; Squamous cell cancer

13 Jun 2025 Efficacy and adverse events data from a phase I trial in Cancer released by Panavance Therapeutics
19 Nov 2024 Pharmacodynamics data from a preclinical study in Cancer released by Panavance Therapeutics
09 Oct 2024 Adverse events and efficacy data from phase I trial in Pancreatic cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy) released by Panavance Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com